276 related articles for article (PubMed ID: 31317482)
1. Thrombotic Risk from Chemotherapy and Other Cancer Therapies.
Debbie Jiang MD; Alfred Ian Lee MD
Cancer Treat Res; 2019; 179():87-101. PubMed ID: 31317482
[TBL] [Abstract][Full Text] [Related]
2. [Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?].
de Moreuil C; Ianotto JC; Eveillard JR; Carrier M; Delluc A
Rev Med Interne; 2016 Jul; 37(7):473-9. PubMed ID: 26833146
[TBL] [Abstract][Full Text] [Related]
3. Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine.
Dammacco F; Vacca A; Procaccio P; Ria R; Marech I; Racanelli V
Clin Exp Med; 2013 May; 13(2):85-97. PubMed ID: 23456539
[TBL] [Abstract][Full Text] [Related]
4. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Zangari M; Fink L; Zhan F; Tricot G
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
[TBL] [Abstract][Full Text] [Related]
5. Thrombosis in multiple myeloma.
Kristinsson SY
Hematology Am Soc Hematol Educ Program; 2010; 2010():437-44. PubMed ID: 21239832
[TBL] [Abstract][Full Text] [Related]
6. A review of the venous thrombotic issues associated with multiple myeloma.
Fotiou D; Gerotziafas G; Kastritis E; Dimopoulos MA; Terpos E
Expert Rev Hematol; 2016 Jul; 9(7):695-706. PubMed ID: 27232265
[TBL] [Abstract][Full Text] [Related]
7. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
[TBL] [Abstract][Full Text] [Related]
9. Update of thrombosis in multiple myeloma.
Leebeek FW
Thromb Res; 2016 Apr; 140 Suppl 1():S76-80. PubMed ID: 27067983
[TBL] [Abstract][Full Text] [Related]
10. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy.
Levine MN
Thromb Haemost; 1997 Jul; 78(1):133-6. PubMed ID: 9198142
[TBL] [Abstract][Full Text] [Related]
11. Drug-related thrombosis in hematologic malignancies.
Nadir Y; Hoffman R; Brenner B
Rev Clin Exp Hematol; 2004 Jun; 8(1):E4. PubMed ID: 16029970
[TBL] [Abstract][Full Text] [Related]
12. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.
Goyal G; Bhatt VR
Future Oncol; 2015; 11(17):2459-70. PubMed ID: 26274336
[TBL] [Abstract][Full Text] [Related]
13. Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.
Palmaro A; Rougé-Bugat ME; Gauthier M; Despas F; Moulis G; Lapeyre-Mestre M
Pharmacoepidemiol Drug Saf; 2017 May; 26(5):578-586. PubMed ID: 28198064
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
15. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
Schoot RA; Kremer LC; van de Wetering MD; van Ommen CH
Cochrane Database Syst Rev; 2013 Sep; (9):CD009160. PubMed ID: 24026801
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
Uaprasert N; Voorhees PM; Mackman N; Key NS
Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism incidence in hematologic malignancies.
Kekre N; Connors JM
Blood Rev; 2019 Jan; 33():24-32. PubMed ID: 30262170
[TBL] [Abstract][Full Text] [Related]
18. Hematologic malignancies and thrombosis.
Elice F; Rodeghiero F
Thromb Res; 2012 Mar; 129(3):360-6. PubMed ID: 22197450
[TBL] [Abstract][Full Text] [Related]
19. Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents.
Santoro M; Romano A; Mancuso S; Siragusa S; DI Raimondo F; Martinelli G; Cerchione C
Panminerva Med; 2021 Mar; 63(1):1-6. PubMed ID: 32955183
[TBL] [Abstract][Full Text] [Related]
20. Thromboprophylaxis in non-surgical cancer patients.
Cohen AT; Gurwith MM; Dobromirski M
Thromb Res; 2012 Apr; 129 Suppl 1():S137-45. PubMed ID: 22682125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
